BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20105083)

  • 1. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy.
    Agarwal A; Agrawal U; Verma S; Mohanty NK; Saxena S
    Immunopharmacol Immunotoxicol; 2010 Jun; 32(2):348-56. PubMed ID: 20105083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
    Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
    J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
    De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
    J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer.
    Pichler R; Gruenbacher G; Culig Z; Brunner A; Fuchs D; Fritz J; Gander H; Rahm A; Thurnher M
    Cancer Immunol Immunother; 2017 Apr; 66(4):427-440. PubMed ID: 28005163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
    Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder.
    Agarwal A; Verma S; Burra U; Murthy NS; Mohanty NK; Saxena S
    Cancer Immunol Immunother; 2006 Jun; 55(6):734-43. PubMed ID: 16283306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
    Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
    Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
    Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
    Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
    Lam JS; Benson MC; O'Donnell MA; Sawczuk A; Gavazzi A; Wechsler MH; Sawczuk IS
    Urol Oncol; 2003; 21(5):354-60. PubMed ID: 14670544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical immunotherapy for superficial bladder cancer.
    Said MT; Abomelha MS; Orkubi SA
    Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
    Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
    N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
    Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
    Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of preventing the recurrence of bladder carcinoma by intravesical instillation of BCG plus IL-2].
    Wen R; Zhou G; Xie S; Lian B; Sun X; Chen J
    Zhonghua Wai Ke Za Zhi; 1998 Apr; 36(4):247-8. PubMed ID: 11825381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT; Soloway MS
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
    Kamat AM; Briggman J; Urbauer DL; Svatek R; Nogueras González GM; Anderson R; Grossman HB; Prat F; Dinney CP
    Eur Urol; 2016 Feb; 69(2):197-200. PubMed ID: 26119560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.